
Chinook Therapeutics (KDNY) Stock Forecast & Price Target
Chinook Therapeutics (KDNY) Analyst Ratings
Based on 10 analyst ratings
Hold
Strong Buy 0%
Buy 20%
Hold 80%
Sell 0%
Strong Sell 0%
Chinook Therapeutics (KDNY) has been analyzed by 10 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 20% recommend Buy, 80% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.
This aggregate rating is based on analysts' research of Chinook Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
This aggregate rating is based on analysts' research of Chinook Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Chinook Therapeutics (KDNY) Analyst Forecast & Price Prediction
Get the latest Chinook Therapeutics (KDNY) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Start investing in Chinook Therapeutics (KDNY)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Chinook Therapeutics (KDNY) Forecast
Analysts have given Chinook Therapeutics (KDNY) a Hold based on their latest research and market trends.
According to 10 analysts, Chinook Therapeutics (KDNY) has a Hold consensus rating as of Jun 22, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.
Wall Street analysts have set a price target of $39.80, reflecting a 0.00% increase from the current stock price.
Financial analysts have set a price target of $39.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.